Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Nationwide Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the DANBIO Register

NCT05421442 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT05421442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05421442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Nationwide Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the DANBIO Register
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
June 13, 2019
Completion date
October 31, 2025
Enrollment
38,396 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis (psa), rheumatoid arthritis (ra)